1,212
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin

, , , &
Pages 1025-1032 | Received 28 Jan 2018, Accepted 09 Apr 2018, Published online: 24 Apr 2018

References

  • Arora P, Sharma S, Garg S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today 7:967–75.
  • Bae HD, Lee K. (2013). On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs. J Control Release 170:358–64.
  • Bae H-D, Lee J, Jin X-H, et al. (2016). Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery. Mol Pharmaceutics 13:3196–205.
  • Duan X, Mao S. (2010). New strategies to improve the intranasal absorption of insulin. Drug Discov Today 15:416–27.
  • El-Andaloussi S, Holm T, Langel U. (2005). Cell-penetrating peptides: mechanisms and applications. Cpd 11:3597–611.
  • Gros E, Deshayes S, Morris MC, et al. (2006). A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochimica Et Biophysica Acta 1758:384–93.
  • Guo Z, Peng H, Kang J, et al. (2016). Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep 4:528–34.
  • He H, Sheng J, David AE, et al. (2013). The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials 34:7733–43.
  • Jarver P, Langel U. (2004). The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9:395–402.
  • Kamei N, Morishita M, Eda Y, et al. (2008). Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 132:21–5.
  • Khafagy el S, Morishita M, Takayama K. (2010). The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int J Pharm 388:209–12.
  • Khafagy E-S, Morishita M, Isowa K, et al. (2009). Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release 133:103–8.
  • Kim M, Kim M, Kim HY, et al. (2011a). A protein transduction domain located at the NH2-terminus of human translationally controlled tumor protein for delivery of active molecules to cells. Biomaterials 32:222–30.
  • Kim M, Maeng J, Jung J, et al. (2011b). Design and evaluation of variants of the protein transduction domain originated from translationally controlled tumor protein. Eur J Pharm Sci 43:25–31.
  • Kristensen M, de Groot AM, Berthelsen J, et al. (2015a). Conjugation of cell-penetrating peptides to parathyroid hormone affects its structure, potency, and transepithelial permeation. Bioconjugate Chem 26:477–88.
  • Kristensen M, Franzyk H, Klausen MT, et al. (2015b). Penetratin-mediated transepithelial insulin permeation: importance of cationic residues and pH for complexation and permeation. Aaps J 17:1200–9.
  • Landreh M, Alvelius G, Willander H, et al. (2012). Insulin solubility transitions by pH-dependent interactions with proinsulin C-peptide. FEBS J 279:4589–97.
  • Liang JF, Yang VC. (2005). Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 335:734–8.
  • Marttin E, Verhoef JC, Romeijn SG, et al. (1995). Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res 12:1151–7.
  • McMartin C, Hutchinson LEF, Hyde R, et al. (1987). Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharma Sci 76:535–40.
  • Merkus FWHM, Schipper NGM, Hermens WAJJ, et al. (1993). Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release 24:201–8.
  • Morris MC, Depollier J, Mery J, et al. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–6.
  • Morris MC, Deshayes S, Heitz F, et al. (2008). Cell-penetrating peptides: from molecular mechanisms to therapeutics. Mol Biol Cell 100:201–17.
  • Nagahara H, Vocero-Akbani AM, Snyder EL, et al. (1998). Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4:1449–52.
  • Sakuma S, Suita M, Masaoka Y, et al. (2010). Oligoarginine-linked polymers as a new class of penetration enhancers. J Control Release 148:187–96.
  • Zatsepin T, Turner J, Oretskaya T, et al. (2005). Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Cpd 11:3639–54.